Cambridge-based Cyted bags €15.4M to revolutionise early cancer diagnostics
Summary
Cambridge-based Cyted, an early cancer diagnostics company, announced on Wednesday, May 17, that it has secured £13.4M (approximately €15.4M) in a round of investment co-led by BGF and Morningside Ventures with participation from private investors. The investment includes a £3.4M (approximately €3.9M) non-dilutive grant from the NHS Cancer Programme announced last month.
Funding
Review available funding amount, funding date, investors, and linked company information related to Cambridge-based Cyted bags €15.4M to revolutionise early cancer diagnostics in the interactive ISVWorld profile.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected